AGP Executive Report
Last update: 8 hours agoCell Therapy Deal: MaxCyte signed a technology license partnership with Genentech to use its ExPERT GTx platform across cell-engineering, analytics, and cGMP workflows. Bradykinin Angioedema Research: Pharvaris published a comprehensive review in Clinical Reviews in Allergy & Immunology backing bradykinin B2 receptor antagonism as a validated approach for bradykinin-mediated angioedema. AI in Pharma Adoption: A new report warns pharma’s AI spend is outpacing real use at key discovery steps, blaming fragmented data readiness and a “trust gap” between models and bench scientists. GLP-1 Coverage Pressure: Coverage gaps for employer benefits and Medicare are still shaping access to GLP-1s, with early Medicare pilot signals showing many older patients choosing injectables. Childhood Obesity Evidence: A meta-analysis suggests GLP-1 weight-loss injections may help some children with obesity, but only under specialist supervision due to side effects and unknown long-term safety. Clinical Trials Reform: FDA’s Project TrialBlazer aims to speed early trial timelines and bring more studies back to the U.S. Stroke Rehab Tech: Marengo Asia Hospitals launched rTMS to support stroke rehabilitation and neuroplasticity. Lung Cancer Screening Gap: A study finds only ~13% of lung cancer patients met low-dose CT screening criteria, highlighting eligibility and uptake barriers. Policy & Payments: A court ruled manufacturers can’t impose certain 340B rebate models without HHS approval; AHA also weighed in on Medicaid supplemental payments, provider tax rules, and price transparency bills. Tariffs Shake Pharma: Trump’s phased up-to-200% tariff plan for imported generic drugs is roiling markets and raising concerns about feasibility, supply-chain timing, and costs. PE-RADS Standardization: A new PE-RADS v2026 reporting framework is set to standardize CT/MR pulmonary embolism imaging communication across care teams. Neuro Workforce Concern (India): Experts warn rising neurological disorders are colliding with a shortage of neurologists, delaying diagnosis and treatment.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.